Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GNR-069 extension study in ITP
NCT05492409Phase 3Completed
- Sponsor
- Generium
- Start
- Mar 2022
- Primary completion
- Apr 2024
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of GNR-069 in immune thrombocytopenia (ITP), sponsored by Generium. Primary endpoints: Frequency and severity of adverse events associated with the use of GNR-069 at 29 weeks, Number of undesirable events of particular interest (Bleeding; Thrombotic/thromboembolic events) at 29 weeks and 2 more. Started Mar 2022; status: completed.
02
Drugs
GNR-069
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT05492409.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05492409.